Josep Llorens - Jul 18, 2023 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Llorens
Stock symbol
HAE
Transactions as of
Jul 18, 2023
Transactions value $
-$162,130
Form type
4
Date filed
7/20/2023, 04:17 PM
Previous filing
May 19, 2023
Next filing
May 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Options Exercise $135K +2.39K +12.95% $56.57 20.9K Jul 18, 2023 Direct F1, F2
transaction HAE Common Stock Options Exercise $146K +2.54K +12.17% $57.60 23.4K Jul 18, 2023 Direct F1, F2
transaction HAE Common Stock Sale -$444K -4.93K -21.07% $90.00 18.5K Jul 18, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -2.39K -33.33% $0.00 4.78K Jul 18, 2023 Common Stock 2.39K $56.57 Direct F1, F3
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -2.54K -25% $0.00 7.61K Jul 18, 2023 Common Stock 2.54K $57.60 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction pursuant to an existing 10b5-1 trading plan dated August 22, 2022.
F2 This number includes unvested restricted stock units previously reported.
F3 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.